Evaluation of antibody response to BNT162b2 mRNA COVID-19 vaccine in patients affected by immune-mediated inflammatory diseases up to 5 months after vaccination
| Autor: | Germano Orrù, Luchino Chessa, Selene Cipri, Gianmario Usai, Andrea Perra, Michela Miglianti, F. Coghe, Federico Meloni, Mauro Giovanni Carta, Davide Firinu, Giulia Costanzo, M. Conti, Giuseppe Fenu, Marcello Campagna, Stefano Del Giacco, Francesca Sedda, Riccardo Cappai, Roberto Littera, Marta Secci |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
COVID-19 Vaccines Booster dose Disease General Biochemistry Genetics and Molecular Biology Immune system Internal medicine Autoimmune disease medicine Humans RNA Messenger BNT162 Vaccine Hematology SARS-CoV-2 business.industry Immunogenicity Vaccination COVID-19 Infant General Medicine medicine.disease Immunoglobulin G Antibody Formation Original Article BNT162b2 Immune-mediated inflammatory diseases IMID business |
| Zdroj: | Clinical and Experimental Medicine |
| ISSN: | 1591-9528 |
| DOI: | 10.1007/s10238-021-00771-3 |
| Popis: | SARS-CoV-2 vaccination with mRNA product BNT162b2 elicited high immunogenicity in healthy subjects in trials. This study aims to better understand the factors that influence the humoral immune response to vaccination against SARS-CoV-2 in patients with immune-mediated inflammatory diseases (IMIDs). We enrolled patients and healthy healthcare workers control group (HCW) that underwent mRNA BNT162b2 vaccination and measured the serum IgG anti-S-RBD response at booster dose (T1), one month after booster dose (T2) and up to 5 months (T3). Demographic, disease-specific and vaccination data were recorded. Vaccination response of 551 participants naïve to SARS-CoV-2 infection were included in HCW and 102 in the IMID group, analyzing separately those on anti-CD20. At T2 all naïve HCW developed anti-S-RBD-IgG, while 94% of IMID responded (p p = 0.031), T2 (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink